UCSF |
|
Stanford University |
Severe Combined Innunodeficiency (SCID) |
AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients |
Recruiting |
|
UCI |
|
Stratetech |
Burn wounds |
StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements |
No longer active |
|
UCSF |
|
Talaris |
Transplanted Organ Rejection |
A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation (FREEDOM-1) |
No longer active |
|
City of Hope |
|
Tessa Therapeutics |
Cancer - Nasopharyngeal Carcinoma |
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngea |
Recruiting |
|
UCSD |
|
Tigenix |
Crohn's Disease |
Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn’s Disease (CD) |
Active, not recruiting |
|
City of Hope |
|
Torque Therapeutics, Inc. |
Cancer - Lymphoma |
TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas |
Recruiting |
|
UC Davis |
|
UC Davis |
B-Cell Leukemia |
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies |
Active, not recruiting |
|
UC Davis |
|
UC Davis |
Cancer - Lymphoma (HIV-Related) |
Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant |
Recruiting |
|
UC Davis |
|
UC Davis |
Cancer - Tongue Dysphagia |
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia |
Recruiting |
|
UC Davis |
|
UC Davis |
Eye - Retinopathy |
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy |
Recruiting |
|
UC Davis |
|
UC Davis/CIRM |
Spina bifida |
Phase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal Myelomeningocele |
Recruiting |
|
UCLA |
Scott Nowicki, MD, PhD
|
UCLA |
Cancer - Solid Tumors |
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies |
No longer active |
|
UCLA |
|
UCLA |
Cancer - Lung |
A Phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC |
Active, not recruiting |
|
UCLA |
|
UCLA |
Cancer |
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM) |
No longer active |
|
UCLA |
|
UCLA |
X-linked Chronic Granulomatous Disease |
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease |
Active, not recruiting |
|
UCLA |
|
UCLA |
Sickle Cell Disease |
Stem Cell Gene Therapy for Sickle Cell Disease |
Recruiting |
|
UCLA |
|
UCLA |
Severe Combined Immunodeficiency (SCID) |
Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID) |
Active, not recruiting |
|
UCSD |
|
UCSD |
Cancer - Breast |
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer |
Active, not recruiting |
|
UCSD & City of Hope |
|
UCSD |
Cancer - Leukemia |
A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies |
Active, not recruiting |
|
UCSD |
|
UCSD |
Cancer - Leukemia |
Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 |
No longer active |
|
UCSD |
|
UCSD |
Cancer - Leukemia |
UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia |
No longer active |
|
UCSD |
|
UCSD & CIRM |
Cystinosis |
Stem cell gene therapy for cystinosis |
Recruiting |
|
UCSD |
|
UCSD/Oncternal |
chronic lymphocytic leukemia |
Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax |
Active, not recruiting |
|
UCSF |
|
UCSF |
Graft versus Host Disease (GvHD) |
An Expanded Access Study of Using the CLINIMACS® Device for Alpha/Beta T-Cell Depletion in Stem Cell Transplant Recipients |
Recruiting |
|
UCSF |
|
UCSF |
Blood Disorder - Alpha Thalassemia Major |
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) |
Recruiting |
|
UC Davis & UCSD |
|
Viacyte |
Type 1 diabetes |
An Open-Label, First-in-Human, Study Evaluating the Safety, Tolerability, and Efficacy of VC-02 Combination Product in Subjects with Type 1 Diabetes Mellitus and Hypoglycemia Unawareness |
No longer active |
|
UCSD |
|
Viacyte |
Diabetes - Type 1 |
Three Year Follow-up Safety Study in Subjects Previously Implanted With VC-01 |
No longer active |
|
UCSD |
|
Viacyte |
Diabetes - Type 1 |
A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness |
No longer active |
|
UCSD |
|
Viacyte |
Diabetes - Type 1 |
A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus |
No longer active |
|